Celina Dubin

This research letter was co-authored by Dr. Celina Dubin, MD, a dermatology resident at the Icahn School of Medicine at Mount Sinai, and was published in the Journal of the American Academy of Dermatology International. SEE THE FULL RANDOMIZATION STUDY IN JAAD INTERNATIONAL HERE: https://www.jaadinternational.org/article/S2666-3287(24)00108-1/fulltext

Dr. Celina Dubin, MD, is a resident physician in dermatology at the Icahn School of Medicine at Mount Sinai. She co-authored this study, which was published in the Journal of Allergy and Clinical Immunology. The study examines atopic dermatitis (AD), a common inflammatory skin disease that affects up to 10% of adults worldwide. Read the original paper here: https://www.jacionline.org/article/S0091-6749(20)30039-7/fulltext

Celina Dubin, MD, a resident physician in dermatology at the Icahn School of Medicine at Mount Sinai, co-authored this study, which appeared in the Journal of the American Academy of Dermatology. The goal of the study was to evaluate the blood proteomic signature of alopecia areata (AA) and identify biomarkers associated with increased disease severity. Read the original paper here: https://www.jaad.org/article/S0190-9622(20)30759-3/abstract

Dr. Celina Dubin, MD, is a resident physician in dermatology at the Icahn School of Medicine at Mount Sinai. She co-authored this study, published in the Journal of Investigative Dermatology (JID). The study evaluated differences in normal skin immune profiles across body locations that are amenable to antigen application and relevant in the context of skin biopsies in clinical trials. Read the original paper here: www.jidonline.org/article/S0022-202X(19)31498-8/fulltext

Drug-Induced Phototoxicity in Vitiligo: The Role of Hydrochlorothiazide in Photosensitivity Dermatitis. Dr. Celina Dubin, MD, is a resident physician in dermatology at the Icahn School of Medicine at Mount Sinai. She co-authored this study, which was published in Case Reports in Dermatological Medicine. The study examines the impact of hydrochlorothiazide, a thiazide diuretic commonly used as an antihypertensive agent, in photosensitivity dermatitis, a multifactorial condition characterized by an exaggerated cutaneous response to ultraviolet (UV) radiation, often exacerbated by exogenous agents, particularly photosensitizing medications. This case highlights the need to recognize drug-induced photosensitivity in vitiligo and to better understand how UV vulnerability and photosensitizing medications interact. Read the Wiley Online Library version of the study here: https://onlinelibrary.wiley.com/doi/full/10.1155/crdm/4302190/

Celina Dubin, MD, a resident physician in dermatology at the Icahn School of Medicine at Mount Sinai, co-authored this study, which was published in the Journal of the American Academy of Dermatology (JAAD). Read the full case study here: https://www.jaadcasereports.org/article/S2352-5126(25)00601-0/fulltext

Hair regrowth in endocrine therapy alopecia with dutasteride treatment in woman with estrogen positive breast cancer. Celina Dubin MD & Angela Lamb MD Read the full version here: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073935/ Or here: https://www.jaadcasereports.org/article/S2352-5126(23)00078-4/fulltext Also appears: https://pubmed.ncbi.nlm.nih.gov/37034026/

Celina Dubin together with; Jacob W. Glickman, Dante Dahabreh, Joseph Han, Ester Del Duca, Yeriel D. Estrada, Ning Zhang, Grace W. Kimmel, Giselle Singer, James G. Krueger, Ana B. Pavel, & Emma Guttman-Yassky present a unique understanding of the phenotype of moderate-to-severe DoubleA with an integrated scalp and serum biomarker model suggesting the systemic nature of the disease, advocating for the need for immune-based systemic treatment. Originally appeared in the Online Library: onlinelibrary.wiley.com/doi/10.1111/all.14814

ASN002 is an oral inhibitor of the Janus kinase/spleen tyrosine kinase signaling pathways, targeting several cytokine axes (T2/T22/T17/T1) and epidermal differentiation. Originally appeared as a medical research paper: www.pubfacts.com/detail/31356921/…l-barrier-marker

To characterize FFA compared to normal and alopecia areata, using broad molecular profiling, and to identify biomarkers linked to disease severity. Originally published in PubMed: pubmed.ncbi.nlm.nih.gov/34044102/

Stand SAFE 2022- "Gun Violence Prevention Initiatives" https://www.standsafe.org/the-team

"One of my earliest memories of Fiskebäckskil is being six years old, spending days sitting on the side of the road making a little store, like a lemonade stand. " Celina Dubin recalls family vacations in Fiskebäckskil - originally appeared in Departures.com: www.departures.com/archive/travel/…backskil-sweden

Firearms are a real "Health Threat" and require the research, education and policy-makin to keep us all healthy. https://www.standsafe.org/the-team

Skin sensitivity may be best defined as self-reported intolerance to application of skincare products. It is commonly believed that individuals with darker skin are generally less sensitive, while those lighter skin are more sensitive. However, there is little objective data correlating sensitivity with skin type or with objective measures of sensitivity.

Co-founders Celina Dubin & Deniz Cataltepe's letter to the editor on the topic of: Hippocratic Oath and firearm violence prevention. Having recently qualified as an MD, May 2022 this topic is even more pressing. Originally appeared in: https://chicago.suntimes.com/2022/7/16/23218484/future-south-shore-cultural-center-chicago-park-district-violence-medicine-letters

The East Harlem School At Exodus House Virtual Speaker Series featured Celina Dubin. Available on Youtube: https://www.youtube.com/watch?v=K5WBjeV3qXw

Frontal fibrosing alopecia was found to be limited to the scalp with inflammatory milieu linked to fibrosis and no systemic inflammation, suggesting possible treatment with immune-targeting therapeutics, according to a genetic analysis.

Genetic analysis: Frontal fibrosing alopecia limited to scalp with no systemic involvement.

Celina Dubin with the team-Jacob W.GlickmanMA CelinaDubinBA YaelRenert-YuvalMD DanteDahabrehBA Grace W.Kimmel MD KelseyAuyeungBA Yeriel D Estrada BS GiselleSingerBS James G.KruegerMD, PhDbAna B.Pavel PhD EmmaGuttman-YasskyMD, PhD. Although there is increased understanding of the alopecia areata (AA) pathogenesis based on studies in scalp tissues, little is known about its systemic profile. Originally appeared as a research paper in Science Direct: https://www.sciencedirect.com/science/article/abs/pii/S0190962220307593

AUTHORS: Benjamin Ungar. Jacob W Glickman. Alexandra K Golant. Celina Dubin. Olga Marushchak. Alyssa Gontzes. Daniela Mikhaylov. Giselle K Singer. Danielle Baum. Nancy Wei. Antonio Sanin. Diana Gruenstein. Mark G Lebwohl. Ana B Pavel. Emma Guttman-Yassky. Background: In the SARS-CoV-2/COVID-19 pandemic, we need to understand the impact of immunomodulatory medications on COVID-19 symptom severity in patients with inflammatory diseases, including the type 2/Th2 polarized skin disease, atopic dermatitis (AD). Originally appeared PubFacts: https://www.pubfacts.com/detail/34737108/COVID-19-Symptoms-Are-Attenuated-in-Moderate-to-Severe-Atopic-Dermatitis-Patients-Treated-with-Dupil

Moderate-to-severe atopic dermatitis (AD) has been associated with significant disease burden and systemic abnormalities and often requires systemic treatments. Currently, safe and effective oral systemic treatments for moderate-to-severe AD are not yet available. ASN002 is an oral inhibitor of the Janus kinase/spleen tyrosine kinase signaling pathways, targeting several cytokine axes (T2/T22/T17/T1) and epidermal differentiation. See the full test version: https://www.jacionline.org/article/S0091-6749(19)30961-3/fulltext

Our approach has the potential to facilitate future development of a personalized medicine approach in AD, and identify the best treatments for individual phenotypes, on the basis of immune and barrier profiles. For the full version of the Study: https://www.jacionline.org/article/S0091-6749(20)30039-7/fulltext

Chronic hand eczema (C.H.E) is a common and burdensome inflammatory skin condition seen in up to 10% of the population, more often in high-risk occupational workers. Originally published in Pub Med: https://pubmed.ncbi.nlm.nih.gov/33408476/

Atopic dermatitis (AD) is the most common inflammatory skin disease. It has a complex pathophysiology, with a combination of immune dysregulation and intrinsic barrier defects driving cutaneous inflammation and allergic symptomatology. See the original Article here: https://www.researchgate.net/publication/352278907_The_IL-4_IL-13_and_IL-31_pathways_in_atopic_dermatitis By Celina Dubin, Ester Del Duca & Emma Guttman-Yassky.

The American Red Cross has recalled 164 lots of antihemophilic factor (AHF) and albumin, due to the potential contamination of this product with the causative agent of Creutzfeld-Jakob disease (CJD).